The company reported fourth-quarter and full-year 2016 earnings.
News & Analysis: Trevena
These three stocks are better left alone.
The company's lead drug met its primary endpoints, but investors are worried about lacking data elsewhere.
On the hunt for a biotech bargain as we head into the new year? If so, our team of healthcare experts think these four biotech stocks deserve a closer look.
If you're looking to add some spice to your portfolio, our Foolish contributors think Shopify, Trevena, and PotashCorp should be on your radar.
Looking for biotech stocks to heat up your portfolio in August? Three Motley Fool healthcare contributors share their picks of the month.
Acadia Pharmaceuticals, Gilead Sciences, and Trevena might be good medicine for your portfolio right now. Here's why.
If you're looking for companies with explosive growth potential, check out these possibilities.
All of these stocks have massive growth potential.
The biotech's experimental heart drug missed the mark.